90991-26-7

Basic information

• Product Name: 5-(3-nitrophenyl)-5-oxopentanoic acid
• CAS NO: 90991-26-7
• Molecular Formula: C₁₁H₁₁NO₅
• Molecular Weight: 237.2087
• Mol File: 90991-26-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 423.5°C at 760 mmHg
• Flash Point: 182.6°C
• Density: 1.34g/cm³
• Vapor Pressure: 6.27E-08mmHg at 25°C
• Refractive Index: 1.572
• CAS DataBase Reference: 5-(3-nitrophenyl)-5-oxopentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(3-nitrophenyl)-5-oxopentanoic acid(90991-26-7)
• EPA Substance Registry System: 5-(3-nitrophenyl)-5-oxopentanoic acid(90991-26-7)

Safety Data

• Hazardous Substances Data: 90991-26-7(Hazardous Substances Data)

Upstream product

• 108-55-4 glutaric anhydride, 
• 71-43-2 benzene 
• 90991-22-3 5-(3-Nitro-phenyl)-5-oxo-pentanoic acid methyl ester 
• 1501-05-9 5-oxo-5-phenylvaleric acid 

Downstream Products

• 95207-74-2 2-(N-acetyl)amino-6,7,8,9-tetrahydrobenzo-cyclohepten-5-one 
• 93431-20-0 5-(3-acetamidophenyl)pentanoic acid 
• 92367-89-0 4-<3-Amino-benzoyl>-buttersaeure 

Relevant articles and documents

Design, synthesis, and evaluation of compounds capable of reducing Pseudomonas aeruginosa virulence

Anti-virulence approaches in the treatment of Pseudomonas aeruginosa (PA)-induced infections have shown clinical potential in multiple in vitro and in vivo studies. However, development of these compounds is limited by several factors, including the lack of molecules capable of penetrating the membrane of gram-negative organisms. Here, we report the identification of novel structurally diverse compounds that inhibit PqsR and LasR-based signaling and diminish virulence factor production and biofilm growth in two clinically relevant strains of P. aeruginosa. It is the first report where potential anti-virulent agents were evaluated for inhibition of several virulence factors of PA. Finally, co-treatment with these inhibitors significantly reduced the production of virulence factors induced by the presence of sub-inhibitory levels of ciprofloxacin. Further, we have analyzed the drug-likeness profile of designed compounds using quantitative estimates of drug-likeness (QED) and confirmed their potential as hit molecules for further development.

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Aspects of Tautomerism. 13. Alkaline Hydrolysis of γ-, δ-, and ε-Keto Esters and their Desoxy Analogues. Geometrical Constraints on Keto Participation

The rates of alkaline hydrolysis of methyl β-benzoylpropionate (I), methyl γ-benzoylbutyrate (II) and methyl δ-benzoylvalerate (III) decrease in the order I>II>III.Keto participation is the predominant pathway in the case of γ-keto esters.Evidence has also been obtained for keto participation in the case of δ-keto esters, whereas no such evidence is available in the case of ε-keto esters studied.